The Intradermal Injection market size is projected to reach US$ 10.36 billion by 2031 from US$ 4.37 billion in 2023. The market is expected to register a CAGR of 11.50% during 2023–2031. The rising strategic developments by manufacturers are likely to remain key trends in the market.
An intradermal (ID) injection is a superficial injection of a substance into the dermis layer of the skin. Certain substances administered via an intradermal (ID) route can result in faster systemic uptake compared with subcutaneous injections. This can lead to a robust immune response for vaccinations, immunology, and novel cancer treatments, as well as faster drug uptake. Additionally, since the administration is nearer to the skin surface, the body's reaction to substances is more easily visible. The mounting prevalence of respiratory diseases and allergies and the increasing adoption of intradermal therapies in aesthetics boost the demand for Intradermal Injections.
As Highlighted by the Aesthetic Plastic Surgery National Databank, in 2020, over 7 million aesthetic procedures were performed in the US, among which the toxins and fillers, were leading with about 3.9 million procedures. Intradermal injections are mainly used to deliver various neurotoxins related to anti-aging treatments. The rising number of aesthetic procedures involving intradermal therapies is increasing the demand for intradermal injections. Additionally, expanding the application of intradermal injections in dermatology for the treatment of skin and hair diseases is likely to offer growth opportunities in the intradermal injection market.
According to a factsheet released by WHO in November 2023, around 10.6 million individuals contracted tuberculosis (TB) globally in 2022. Many respiratory diseases, including TB, influenza, and COVID-19, can be diagnosed by tuberculin skin test, which involves intradermal injection. The increasing prevalence of these diseases has led to an increase in the development of intradermal injections for treatment and diagnosis. For instance, in 2020, the FDA approved Fluzone, an intradermal vaccine of influenza developed by Sanofi. The injection is rapidly overtaking the influenza vaccine market and replacing the congenital treatments for these diseases. In addition, Pfizer received approval for its intradermal COVID-19 vaccine named Comirnaty for people above 16 years of age. Such developments by the market players are boosting the global Intradermal Injection market.
Intradermal therapy, also called mesotherapy, involves a series of micro-injections of active ingredients into the superficial layer of the skin. While it has various clinical applications, it can be instrumental in dermatology for treating many patients. Various studies are being conducted to assess the efficacy and benefits of intradermal injections in treating dermatological conditions. For instance, in an article published in the Journal of Plastic & Reconstructive Surgery in April 2024, a study was carried out to investigate the impact of mechanical factors (syringe and needle size, length, and skin booster viscosity) on the force needed for intradermal injection in porcine skin. The study concluded that the administration of skin boosters via intradermal injections with smaller syringe diameters under optimal conditions maximizes rejuvenating outcomes. These ongoing studies are anticipated to help in the development of potential intradermal treatments in dermatology, offering lucrative growth opportunities in the intradermal injection market.
Key segments that contributed to the derivation of the intradermal injection market analysis are method, application, and end user.
The geographic scope of the Intradermal Injection market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America. Asia Pacific is estimated to grow with the highest CAGR in the coming years.
The Intradermal Injection market in North America is analyzed based on the three major countries: the US, Canada, and Mexico. The US is projected to have the largest share of the North American intradermal Injection market in 2023.
TB is one of the major bacterial infections in well-matured countries, including the US. According to the statistics published by the Centres of Disease Control and Prevention (CDC) in 2024, about 13 million individuals are living in the US with latent TB, while in 2022, 8,331 cases of TB were reported in the US, with a rate of 2.5 cases per 100,000 people. As the tuberculin skin test is the main test for the disease diagnosis, the demand for intradermal injections is high, which is increasing the market size of this segment.
Furthermore, the increasing adoption of technological advancements and rising R&D activities are projected to accelerate the growth of the intradermal injections market.
The regional trends and factors influencing the Intradermal Injection Market throughout the forecast period have been thoroughly explained by the analysts at Insight Partners. This section also discusses Intradermal Injection Market segments and geography across North America, Europe, Asia Pacific, Middle East and Africa, and South and Central America.
| Report Attribute | Details |
|---|---|
| Market size in 2023 | US$ 4.37 Billion |
| Market Size by 2031 | US$ 10.36 Billion |
| Global CAGR (2023 - 2031) | 11.5% |
| Historical Data | 2021-2022 |
| Forecast period | 2024-2031 |
| Segments Covered |
By Method
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
The Intradermal Injection Market market is growing rapidly, driven by increasing end-user demand due to factors such as evolving consumer preferences, technological advancements, and greater awareness of the product's benefits. As demand rises, businesses are expanding their offerings, innovating to meet consumer needs, and capitalizing on emerging trends, which further fuels market growth.
Market players density refers to the distribution of firms or companies operating within a particular market or industry. It indicates how many competitors (market players) are present in a given market space relative to its size or total market value.
Major Companies operating in the Intradermal Injection Market are:
Disclaimer: The companies listed above are not ranked in any particular order.
The Intradermal Injection market is evaluated by gathering qualitative and quantitative data from primary and secondary research, which includes essential corporate publications, association data, and databases. A few of the developments in the Intradermal Injection market are listed below:
The “Intradermal Injection Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
North America dominated the Intradermal Injection market in 2023.
Factors including increasing prevalence of respiratory diseases and use of intradermal injection in aesthetics are the driving factors for the Intradermal Injection market growth.
The rising strategic developments by manufacturers are future trends in the market.
BD, Terumo Corporation, NanoPass, Pharmajet, Idevax, Eunsung Global, West Pharmaceutical Services, Inc., Crossject, Cardinal Health Inc, Hindustan Syringes and Medical Devices Ltd are some leading players operating in the intradermal injection market.
The Intradermal Injection market is estimated to reach US$ 10.36 billion by 2031.
The intradermal injection market is anticipated to grow at a CAGR of 11.50% from 2023 to 2031.